Insider Selling: Sera Prognostics (NASDAQ:SERA) CEO Sells 20,755 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the sale, the chief executive officer directly owned 871,999 shares in the company, valued at $1,813,757.92. This represents a 2.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Trading Down 6.1%

SERA stock traded down $0.13 during midday trading on Wednesday, reaching $2.00. The stock had a trading volume of 99,259 shares, compared to its average volume of 58,147. The company’s fifty day simple moving average is $2.03 and its 200 day simple moving average is $2.56. The company has a market cap of $78.32 million, a price-to-earnings ratio of -3.08 and a beta of 0.94. Sera Prognostics, Inc. has a 52-week low of $1.43 and a 52-week high of $4.09.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. Craig Hallum initiated coverage on Sera Prognostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently modified their holdings of SERA. Segall Bryant & Hamill LLC acquired a new position in shares of Sera Prognostics during the first quarter worth about $193,000. Arkadios Wealth Advisors purchased a new stake in Sera Prognostics during the first quarter worth approximately $25,000. Cetera Investment Advisers purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $74,000. Barclays PLC lifted its stake in Sera Prognostics by 267.4% during the fourth quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after purchasing an additional 26,726 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $203,000. 54.64% of the stock is owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.